Physician profile
Celia B Servin
NPI 1326336371
$10,501.52
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,751 · 2020: $1,505 · 2021: $2,558 · 2022: $2,259 · 2023: $1,407 · 2024: $20.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,573.11 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,178.77 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $892.40 | 2019-2023 | |
| Abbvie INC. | $725.76 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $607.18 | 2019-2023 | Jardiance, Synjardy |
| Gilead Sciences, INC. | $603.53 | 2019-2023 | |
| Lilly USA, LLC | $576.22 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $504.08 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $477.63 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $465.62 | 2019-2022 | |
| Amgen INC. | $254.15 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.44 | 2022-2023 | |
| Pfizer INC. | $224.81 | 2019-2023 | |
| Amarin Pharma, INC. | $197.17 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $183.51 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Servin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.